Editorial | Will Clinical Trials Endure Under the New FDA?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Source: WSJ
Impact on Patients: The rejection of Replimune’s RP1 immunotherapy for metastatic melanoma negatively affects patients and hinders pharmaceutical development.
Importance of Clinical Trials: Patients participating in clinical trials are crucial for advancing research, often making personal sacrifices for the potential benefit of future treatments.
Expectations from FDA: Participants in trials hope for FDA approval of treatments that are proven safe and effective, which is a key aspect of their involvement.
Consequences for Research: The decision undermines the U.S. clinical-trial system, potentially discouraging patient participation and slowing down the development of new therapies.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like REPL with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on REPL
Wall Street analysts forecast REPL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REPL is 11.43 USD with a low forecast of 3.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 7.360
Low
3.00
Averages
11.43
High
18.00
Current: 7.360
Low
3.00
Averages
11.43
High
18.00
About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alto Neuroscience and Others Under Investigation for Shareholder Claims
- Shareholder Lawsuit Investigation: Johnson Fistel, PLLP is investigating shareholder claims against Alto Neuroscience (NYSE: ANRO) and others, alleging breaches of fiduciary duty that could lead to corporate governance reforms and return of funds.
- False Statements Allegations: Alto Neuroscience is accused of making false statements regarding the efficacy of its lead drug ALTO-100, resulting in investor losses when the truth was revealed, negatively impacting the company's reputation and stock price.
- Anticompetitive Pricing Practices: Atkore Inc. (NYSE: ATKR) faces a securities class action lawsuit alleging executives failed to disclose anticompetitive pricing practices related to PVC pipe products, which may lead to legal risks and diminished shareholder trust.
- Safety Risks Concealment: Fly-E Group (NASDAQ: FLYE) is accused of downplaying safety risks associated with its lithium battery technology in electric mobility products, leading to a stock price decline and harming investor interests, affecting the company's future growth prospects.
Continue Reading
Replit Launches Natural Language App Development Feature, Enabling Rapid User Deployment
- Feature Launch: Replit's new mobile app feature allows users to create and publish apps using only natural language prompts, significantly reducing the time from concept to launch, enabling users to develop apps in minutes and submit them to the App Store in days.
- Monetization Integration: The feature's integration with Stripe allows users to easily monetize their apps, marking a significant advancement for Replit in the AI-powered coding space and enhancing market competitiveness for small businesses and creators.
- Increased Market Risks: As more vibe-coding products come online, software companies face intensified competition, with the iShares Expanded Tech-Software Sector ETF dropping 11% in the last three months, reflecting investor concerns about the risks posed by AI coding products.
- Security Concerns: A new study from Tenzai highlights critical security vulnerabilities in apps generated by AI coding agents like Replit and Claude Code, raising potential risks for cyberattacks, prompting users to carefully consider security before publishing.
Continue Reading